Selank dosing evidence
Selank has been studied in humans, and none of those studies published a dose. That is the unusual shape of this entry: the problem is not that nobody looked, it is that the number is missing from the papers. The literature holds a randomised comparison against medazepam in sixty-two patients with generalised anxiety disorder and neurasthenia, a comparison against phenazepam in sixty patients with phobic-anxiety and somatoform disorders, a randomised study of Selank added to phenazepam in seventy patients, and a placebo-controlled resting-state fMRI study in fifty-two healthy participants. Not one of them states the dose, the concentration, the route or the length of the course. The only quantitative figures anywhere in this compound's literature are animal doses, and an animal dose can never back a human range. Selank is a synthetic heptapeptide, given as a nasal solution, registered as a prescription anxiolytic in Russia and approved nowhere in North America or Western Europe. So this page states no dose.
Curated by Dosavy from published literature and regulator labels. Published 11 September 2026, last reviewed 11 September 2026. No clinician reviews this page.
No established human dose
No human trial has established a dose for Selank. There is no evidence-based dose to give, and this page does not give one.
What the evidence says
Selank HAS been studied in humans, and this entry is not claiming otherwise: the corpus contains a randomised comparison of Selank against medazepam in 62 patients with generalised anxiety disorder and neurasthenia (PMID 18454096), a comparison against phenazepam in 60 patients with phobic-anxiety and somatoform disorders (PMID 25176261), a randomised study of Selank added to phenazepam in 70 patients (PMID 26356395), and a placebo-controlled resting-state fMRI study in 52 healthy participants (PMID 32342318). What is missing is the number: not one of these publications states the dose, the concentration, the route, or the length of the course. The only quantitative dose figures anywhere in this compound's corpus are animal doses: 100 mcg/kg/day intraperitoneally in rats under social stress (PMID 32621722) and 0.3 mg/kg intraperitoneally in rats in morphine withdrawal (PMID 36322304), and an animal dose can never back a human range. A dosing range is therefore unpublishable for Selank even though the compound is not unstudied. The 250-1000 mcg/day intranasal figure recorded under community_practice is what US wellness clinics publish and dispense; it is a market observation, it has no trial behind it, and it must never be presented as a studied dose.
Selank at a glance
- Category
- Sleep / nootropic
- Half-life
- Not established
- Routes
- Intranasal
- Regulatory status
- Not approved
- Also sold as
- Selank, N-acetyl selank, TP-7, Thr-Lys-Pro-Arg-Pro-Gly-Pro
Mechanism
A synthetic heptapeptide built from the endogenous immunopeptide tuftsin (Thr-Lys-Pro-Arg) extended with Pro-Gly-Pro to resist enzymatic degradation. Its proposed anxiolytic mechanism is inhibition of enkephalin-degrading enzymes: in plasma from patients with anxiety and phobic disorders, Selank dose-dependently inhibited enzymatic hydrolysis of enkephalin (IC50 15 microM), more potently than bacitracin or puromycin, and generalised anxiety was itself associated with shortened enkephalin half-life. A clinical study measuring leu-enkephalin half-life in patients treated with Selank found it rose during treatment. In rodents it also modulates stress-induced cytokine release. The mechanism is plausible and partly measured in humans; it is not a dosing basis.
Reconstitution
The Russian product is a ready-made nasal solution and is not reconstituted. Research powder has no validated reconstitution procedure or potency standard, so a mcg-per-spray figure describes only one seller's own preparation.
Storage
No approved label defines storage. The Russian pharmaceutical product is a ready-made nasal solution; material sold elsewhere is a lyophilised research powder with no pharmaceutical storage standard.
Frequency in practice
Intranasal spray, once to three times daily in short courses, per commercial listings. No trial-established schedule exists.
Regulatory
Registered as a prescription anxiolytic in Russia; never approved by the FDA or EMA and not approved anywhere in North America or Western Europe. Outside Russia it is sold as a research chemical or compounded by wellness clinics, with no approved dose, potency or purity standard.
What to know before anything else
Not FDA- or EMA-approved. No approved label defines a dose, contraindications, or drug interactions.
Human trials of Selank exist and report an anxiolytic effect, but none of them publishes the dose that produced it. Any specific microgram figure you encounter for Selank (including the one recorded under community_practice here) comes from a seller or a clinic, not from a trial.
The trials that exist compared Selank against benzodiazepines (phenazepam, medazepam) in patients with diagnosed anxiety disorders, several of them as an add-on to the benzodiazepine rather than as a replacement. That is not the same as an over-the-counter anxiolytic for healthy adults.
All human studies are Russian-language, single-country, and small (roughly 60-70 patients each). There is no independent replication outside Russia and no long-term safety data.
Selank is a tuftsin analogue and tuftsin is an immunomodulator. Effects in autoimmune disease or alongside immunosuppressive therapy have not been studied.
Selank questions
Is there an established dose for Selank?
No, and the reason is specific. Human trials of Selank exist and report an anxiolytic effect, but none publishes the dose that produced it: not the amount, not the concentration, not the route, not the course length. A range is therefore unpublishable here even though the compound is not unstudied. Any microgram figure you meet for Selank comes from a seller or a clinic, not a trial, and this page does not repeat one.
Does Selank work for anxiety?
The trials report that it does, and the trials are small. There is a randomised comparison against medazepam in sixty-two patients with generalised anxiety disorder and neurasthenia (PMID 18454096), a comparison against phenazepam in sixty patients with phobic-anxiety and somatoform disorders (PMID 25176261), a randomised study of Selank added to phenazepam in seventy patients (PMID 26356395), and a placebo-controlled resting-state fMRI study in fifty-two healthy participants (PMID 32342318). All of the clinical work is Russian-language and single-country, with no independent replication elsewhere and no long-term safety data. Several of those trials tested Selank alongside a benzodiazepine rather than as a replacement for one, in patients with diagnosed anxiety disorders, which is not the same thing as an anxiolytic for healthy adults.
How does Selank work?
It is a synthetic heptapeptide built from tuftsin, an endogenous immunopeptide, extended with Pro-Gly-Pro to resist enzymatic degradation. The proposed anxiolytic mechanism is inhibition of enkephalin-degrading enzymes: in plasma from patients with anxiety and phobic disorders, Selank inhibited enzymatic hydrolysis of enkephalin dose-dependently and more potently than bacitracin or puromycin, and generalised anxiety was itself associated with a shortened enkephalin half-life. A clinical study measuring leu-enkephalin half-life in treated patients found it rose during treatment. In rodents it also modulates stress-induced cytokine release. The mechanism is plausible and partly measured in humans, and it is still not a dosing basis.
What is the difference between Selank and Semax?
Different peptides with different parents. Selank is built from tuftsin, and its partly measured human mechanism runs through enkephalin degradation. Semax is a heptapeptide analogue of the ACTH(4-10) fragment carrying the same Pro-Gly-Pro tail, and animal work attributes its nootropic effect to BDNF synthesis and to serotonergic and dopaminergic activation. Both are intranasal, and neither is approved by the FDA or the EMA. The evidence differs where it counts: this library records published human dosing figures for Semax and none at all for Selank.
Is Selank approved, and is it legal?
It is registered as a prescription anxiolytic in Russia, and it has never been approved by the FDA or the EMA or anywhere else in North America or Western Europe. Outside Russia it is sold as a research chemical or compounded by wellness clinics, with no approved dose, potency or purity standard. The Russian product is a ready-made nasal solution; material sold elsewhere is a lyophilised research powder with no pharmaceutical storage standard.
What are the safety questions about Selank?
The unstudied ones. Selank is a tuftsin analogue and tuftsin is an immunomodulator, so what it does in autoimmune disease or alongside immunosuppressive therapy is a live question, and it has not been studied. There is no approved label to define contraindications or drug interactions, no independent replication of the trials outside Russia, and no long-term safety data of any kind. The trials that do exist ran in patients with diagnosed anxiety disorders, several of them on a benzodiazepine at the same time, and that is the only population these safety observations come from.
Why does every seller list a different microgram figure for Selank?
Because each figure describes that seller's own preparation rather than a studied dose. No trial states a Selank dose, so there is nothing for the numbers to be anchored to. The Russian product is a ready-made nasal solution and is not reconstituted at all, while research powder has no validated reconstitution procedure or potency standard, so a per-spray figure says only how one seller mixed and measured its own bottle. That is also why this page carries no mixing calculator: there is no vial arithmetic to do for a nasal solution, and no established dose to do it against.
The rest of the math
- Reconstitution calculatorThe full version of the tool above, with syringe barrel sizes and IU conversion.
- Vial longevityHow many doses a vial holds and the date it runs out.
- Cost per doseVial price against doses drawn, so two vial sizes can be compared honestly.
- Half-life and decayFirst-order clearance, time to steady state, and what remains at a given hour.
Same class as Selank
You worked out the draw. Now log this dose.
A calculator answers once and forgets. Dosavy keeps the concentration you mixed, the doses you actually took, and a reminder for the next one, with the same evidence labels you see on this page.